Recent findings on psychosocial outcomes of gender-affirming medical care for transgender youth.
Weixel. Tara T; Whitehead. Jax J; Chen. Diane D
Key Findings
- GnRH agonist treatment (pubertal suppression) is linked to lower rates of depression and anxiety in transgender adolescents.
- When GnRH suppression is combined with gender‑affirming hormone therapy, overall wellbeing and quality of life improve further.
- Robust, multidisciplinary support (mental health, social, medical) is crucial for maximizing these positive outcomes.
Practical Outcomes
- For most biohackers, the data are not directly actionable because the benefits are specific to gender‑diverse youth and rely on careful medical supervision. The study does suggest that GnRH agonists can positively affect mood when used in a well‑structured, supportive protocol, but off‑label use without professional oversight is not recommended.
Summary
Recent long‑term studies show that using GnRH agonists (like gonadorelin) to pause puberty, followed by gender‑affirming hormone therapy, helps transgender youth feel better mentally and reduces gender‑related distress. The benefits are tied to comprehensive, supportive care rather than the drug alone.
Abstract
Many transgender and gender diverse (TGD) youth experience gender dysphoria which can exacerbate mental health risk. Gender-affirming medical interventions, such as pubertal suppression using gonadotropin-releasing hormone agonists (GnRHa) and gender-affirming hormone therapy (GAHT), primarily aim to alleviate gender dysphoria, with overall goals of optimizing wellbeing. Here we discuss prospective, longitudinal studies published in the last 5 years examining mental health outcomes of GnRHa and GAHT for TGD youth and young adults, contextualize these findings within the current socio-political climate, and elaborate on the need for robust and comprehensive gender-affirming care for TGD youth.
Study Information
pubmed
2025
2025-11-04T00:00:00.000Z
10.1210/clinem/dgaf605